Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  Next»
    Study title: A multi-centre, double-blind, controlled trial of prophylaxis against cytomegalovirus infections in bone marrow transplant patients using intravenous acyclovir followed by oral acyclovir.
    Active substance: ACICLOVIR
    Study summary document link (including results): Study H14-304 Aciclovir.xls
    View full study record
    Document reference: 46215
    Study title: PROPHYLAXIS AGAINST CMV IN BONE MARROW TRANSPLANT RECIPIENTS WITH INTRAVENOUS ZOVIRAX
    Active substance: ACICLOVIR
    Study summary document link (including results): Study ZOVlRAX#142 Aciclovir.xls
    View full study record
    Document reference: 46212
    Study title: Dalieri M, Gnius A, Gómez S, Pernas J, Fabeiro M, Prozzi M: Uso de L-glutamina en niños con transplante de modula ósea / Glutamine use in children with bone marrow transplantation. RNC 2003; 12: 54-59 abstract (language Spanish)Dalieri M, Gnius A, Gómez S, Pernas J, Fabeiro M, Prozzi M: Uso de L-glutamina en niños con transplante de modula ósea / Glutamine use in children with bone marrow transplantation. RNC 2003; 12: 54-59 abstract (language Spanish)
    Active substance: ALANYL-GLUTAMINE
    Study summary document link (including results):
    View full study record
    Document reference: 46315
    Study title: POG 9407 Study I : induction intensification and allogeneic bone marrow transplant in infant ALL
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21930
    Study title: Suttorp M et al, Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias, Bone Marrow Transplant. 1989 Dec;4 Suppl 4:144-8
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26906
    Study title: Santana VM et al Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors Bone Marrow Transplant 1992 Nov;10(5):457-62
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26750
    Study title: Santana VM et al, Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors, Bone Marrow Transplant 1992 Nov;10(5):457-62
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26804
    Study title: Gonzalez-Vicent, M., Madero, L., Sevilla, J., et al, Ramirez, M. and Diaz, M. A. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children Bone Marrow Transplantation 34(12): 1077-1081.
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26958
    Study title: Duerst RE et al, Allogeneic bone marrow transplantation for children with acute leukemia:, cytoreduction with fractionated total body irradiation, high-dose etoposide and, cyclophosphamide, Bone Marrow Transplant. 2000 Mar;25(5):489-94
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26880
    Study title: Bisogno G et al Intensive chemotherapy for children and young adults with metastatic primitive neuroectodermal tumors of the soft tissue.Bone Marrow Transplant 2002 Sep;30(5):297-302
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26689
    Study title: Bouffet E et al, Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas, Eur J Cancer. 1997 Jan;33(1):91-5
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26840
    Study title: Zucker JM et al , Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients, Bone Marrow Transplant. 1991;7 Suppl 2:91. No abstract available
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26954
    Study title: Petersen FB et al, Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study, Bone Marrow Transplant. 1992 Jul;10(1):83-8
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26894
    Study title: Bunin N et al, Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study, Bone Marrow Transplant. 2003 Sep;32(6):543-8
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26873
    Study title: Kang HJ et al, Autologous peripheral blood stem cell transplantation with BCVAC conditioning in , childhood acute myeloid leukemia, Bone Marrow Transplant. 2004 Mar;33(5):471-6
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26887
    Study title: Valteau-Couanet D et al, Phase I study of high-dose continuous intravenous infusion of VP-16 in, combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma, Bone Marrow Transplant. 1996 Apr;17(4):485-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26947
    Study title: von Bueltzingsloewen A et al, Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle, Bone Marrow Transplant. 1995 Oct;16(4):521-7
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26908
    Study title: Boenig, H., Silbermann, S., Weller, S., et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF): Results of a prospective randomised monocentre study Bone Marrow Transplantation 28(3): 259-264.Boenig, H., Silbermann, S., Weller, S., et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF): Results of a prospective randomised monocentre study Bone Marrow Transplantation 28(3): 259-264.
    Active substance: FILGASTRIM
    Study summary document link (including results): Bibliography - Neupogen[2].pdf
    View full study record
    Document reference: 27275
    Study title: Fleischhack, G., Hasan, C., Graf, N., et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial British Journal of Haematology 102(3): 647-655.Fleischhack, G., Hasan, C., Graf, N., et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial British Journal of Haematology 102(3): 647-655.
    Active substance: FILGASTRIM
    Study summary document link (including results):
    View full study record
    Document reference: 27281
    Study title: EFFICACY AND TOLERATION OF AN ANTIFUNGAL PROPHYLAXIS OF FLUCONAZOLE IN PATIENTS HAVING UNDERGONE BONE MARROW TRANSPLANTATION.
    Active substance: FLUCONAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 27425
    1  2  3  4  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:36:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA